Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Although many patients with end-stage cancer are offered chemotherapy to improve quality of life (QOL), the association between chemotherapy and QOL amid progressive metastatic disease has not been well-studied. American Society for Clinical Oncology guidelines recommend palliative chemotherapy only for solid tumor patients with good performance status. OBJECTIVE: To evaluate the association between chemotherapy use and QOL near death (QOD) as a function of patients' performance status. DESIGN, SETTING, AND PARTICIPANTS: A multi-institutional, longitudinal cohort study of patients with end-stage cancer recruited between September 2002 and February 2008. Chemotherapy use (n = 158 [50.6%]) and Eastern Cooperative Oncology Group (ECOG) performance status were assessed at baseline (median = 3.8 months before death) and patients with progressive metastatic cancer (N = 312) following at least 1 chemotherapy regimen were followed prospectively until death at 6 outpatient oncology clinics in the United States. MAIN OUTCOMES AND MEASURES: Patient QOD was determined using validated caregiver ratings of patients' physical and mental distress in their final week. RESULTS: Chemotherapy use was not associated with patient survival controlling for clinical setting and patients' performance status. Among patients with good (ECOG score = 1) baseline performance status, chemotherapy use compared with nonuse was associated with worse QOD (odds ratio [OR], 0.35; 95% CI, 0.17-0.75; P = .01). Baseline chemotherapy use was not associated with QOD among patients with moderate (ECOG score = 2) baseline performance status (OR, 1.06; 95% CI, 0.51-2.21; P = .87) or poor (ECOG score = 3) baseline performance status (OR, 1.34; 95% CI, 0.46-3.89; P = .59). CONCLUSIONS AND RELEVANCE: Although palliative chemotherapy is used to improve QOL for patients with end-stage cancer, its use did not improve QOD for patients with moderate or poor performance status and worsened QOD for patients with good performance status. The QOD in patients with end-stage cancer is not improved, and can be harmed, by chemotherapy use near death, even in patients with good performance status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Pfeiffer, E. (1975) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1975.tb00927.x · Cited by 5,321
Tunis (2003) · doi:10.1001/jama.290.12.1624 · Cited by 1,724
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Trends in the Aggressiveness of Cancer Care Near the End of Life
Earle, C. C., Neville, B. A., Landrum, M. B., Ayanian, J. Z., Block, S. D., & Weeks, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.136 · Cited by 987
Teno, J. M., Gozalo, P. L., Bynum, J. P. W., Leland, N. E., Miller, S. C., Morden, N. E., Scupp, T., Goodman, D. C., & Mor, V. (2013) · JAMA · doi:10.1001/jama.2012.207624 · Cited by 966
Schnipper, L. E., Smith, T. J., Raghavan, D., Blayney, D. W., Ganz, P. A., Mulvey, T. M., & Wollins, D. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8375 · Cited by 649
Greer, J. A., Pirl, W. F., Jackson, V. A., Muzikansky, A., Lennes, I. T., Heist, R. S., Gallagher, E. R., & Temel, J. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.7996 · Cited by 574
Prognostic Factors for Survival in Patients With Inoperable Lung Cancer 2
(1980) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/65.1.25 · Cited by 564
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Kassam, F., Enright, K., Dent, R., Dranitsaris, G., Myers, J., Flynn, C., Fralick, M., Kumar, R., & Clemons, M. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.005 · Cited by 474
Wright, A. A., Zhang, B., Keating, N. L., Weeks, J. C., & Prigerson, H. G. (2014) · BMJ · doi:10.1136/bmj.g1219 · Cited by 340
Self-citationChemotherapy Use among Medicare Beneficiaries at the End of Life
Emanuel, E. J., Young-Xu, Y., Levinsky, N. G., Gazelle, G., Saynina, O., & Ash, A. S. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-8-200304150-00011 · Cited by 317
Factors Important to Patients' Quality of Life at the End of Life
Zhang, B., Nilsson, M. E., & Prigerson, H. G. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.2364 · Cited by 308
Self-citationFumoleau, P., Largillier, R., Clippe, C., Dièras, V., Orfeuvre, H., Lesimple, T., Culine, S., Audhuy, B., Serin, D., Curé, H., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.007 · Cited by 305
Resurrecting Treatment Histories of Dead Patients: A Study Design That Should Be Laid to Rest
Bach, P. B., Schrag, D., & Begg, C. B. (2004) · JAMA · doi:10.1001/jama.292.22.2765 · Cited by 255
Massarelli, E., Andre, F., Liu, D. D., Lee, J. J., Wolf, M., Fandi, A., Ochs, J., Le Chevalier, T., Fossella, F., & Herbst, R. S. (2003) · Lung Cancer · doi:10.1016/s0169-5002(02)00308-2 · Cited by 200
Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life
(2015) · Military Medicine · doi:10.7205/milmed-d-15-00005 · Cited by 177
The effect on survival of continuing chemotherapy to near death
Saito, A. M., Landrum, M. B., Neville, B. A., Ayanian, J. Z., & Earle, C. C. (2011) · BMC Palliative Care · doi:10.1186/1472-684x-10-14 · Cited by 155
Why do our patients get chemotherapy until the end of life?
Braga, S. A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr416 · Cited by 111
Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care
Kelly, R. J., & Smith, T. J. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70578-3 · Cited by 86
Salloum, R. G., Smith, T. J., Jensen, G. A., & Lafata, J. E. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.04.019 · Cited by 51
Abbott, C. H., Prigerson, H. G., & Maciejewski, P. K. (2013) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2013.09.011 · Cited by 49
Self-citationLamont, E. B., Schilsky, R. L., He, Y., Muss, H. B., Cohen, H. J., Hurria, A., Meilleur, A., Kindler, H. L., Venook, A. P., Lilenbaum, R., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju336 · Cited by 36
Anders, C. K., & Peppercorn, J. M. (2009) · Cancer Investigation · doi:10.1080/07357900802484944 · Cited by 11
Cited by
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Integration of oncology and palliative care: a Lancet Oncology Commission
Kaasa, S., Loge, J. H., Aapro, M., Albreht, T., Anderson, R., Bruera, E., Brunelli, C., Caraceni, A., Cervantes, A., Currow, D. C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30415-7 · Cited by 830
Ooft, S. N., Weeber, F., Dijkstra, K. K., McLean, C. M., Kaing, S., van Werkhoven, E., Schipper, L., Hoes, L., Vis, D. J., van de Haar, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aay2574 · Cited by 813
Early palliative care for adults with advanced cancer
Haun, M. W., Estel, S., Rücker, G., Friederich, H.-C., Villalobos, M., Thomas, M., & Hartmann, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011129.pub2 · Cited by 757
Non-invasive early detection of cancer four years before conventional diagnosis using a blood test
Chen, X., Gole, J., Gore, A., He, Q., Lu, M., Min, J., Yuan, Z., Yang, X., Jiang, Y., Zhang, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17316-z · Cited by 628
Metadata
- Authors
- Prigerson, H. G., Bao, Y., Shah, M. A., Paulk, M. E., LeBlanc, T. W., Schneider, B. J., Garrido, M. M., Reid, M. C., Berlin, D. A., Adelson, K. B., Neugut, A. I., & Maciejewski, P. K.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2015-09-01
- Volume
- 1
- Issue
- 6
- Pages
- 778
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2149577037
- Cited by
- 645
- References
- 26
- FWCI
- 61.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.